• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

Rare case of homozygous ifnar1 deficiency in a samoan child with disseminated varicella after vaccination
Autosomal recessive interferon alpha/beta receptor 1 (IFNAR1) deficiency increases susceptibility to live-attenuated vaccines and wild-type viruses. Currently 16 cases, half with Polynesian ancestry have been reported since the discovery in 2019. Most cases present with severe MMR or yellow fever vaccine-related disease. Some cases report severe SARS-CoV-2, herpes simplex, and enterovirus. Varicella vaccine-related disease has been hypothesized but not previously reported.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: M. Revier, N. Scanlon, M. Lee, C. Collins, S. Laubach Tags: M247 Source Type: research

How effective is the monkeypox vaccine? Scientists scramble for clues as trials ramp up
When mo nkeypox suddenly started spreading globally in May, the world was fortunate in one respect: a vaccine was available. MVA, originally developed by Bavarian Nordic as a smallpox vaccine, was already licensed for monkeypox in Canada and the United States. EU regulators have since followed suit. Vaccine supplies are limited, and no doses have been shared with countries in Africa that have long been affected by monkeypox. But in Europe and North America, clinics have by now delivered thousands of doses to people in high-risk groups. There’s little doubt the vaccine can help, but that’s about all that’s...
Source: Science of Aging Knowledge Environment - August 10, 2022 Category: Geriatrics Source Type: research

A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
Am J Epidemiol. 2022 Feb 12:kwac030. doi: 10.1093/aje/kwac030. Online ahead of print.ABSTRACTThe recombinant herpes zoster vaccine (RZV), approved as a 2-dose series in the U.S. in October 2017, has proven highly effective and generally safe. However, a small risk of Guillain-Barré syndrome (GBS) after vaccination was identified post-approval, and questions remain about other possible adverse events. This data-mining study assessed RZV safety in the U.S. using the self-controlled tree-temporal scan statistic, scanning data on thousands of diagnoses recorded during follow-up to detect any statistically unusual temporal clu...
Source: Am J Epidemiol - February 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research

Active Symptom-Based Surveillance of Adverse Events Following Immunization among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala
CONCLUSION: All the adverse reactions were of a minor type and non-serious. Side effects were less common in older adults (>60 years). Reactions to the second dose were lesser in intensity and frequency. Younger age, history of allergy, and comorbidities, particularly asthma were found to be major predictors for the development of adverse events and require more watchful vaccine administration.PMID:35135453 | DOI:10.2174/1574886317666220207120649
Source: Current Drug Safety - February 9, 2022 Category: Drugs & Pharmacology Authors: Maria Jose Priyanka Rajmohan Joe Thomas Swathi Krishna Beena Antony Unnikrishnan U G Elsy M I Raphael M P Ponnu Jose Lucy Raphael Praveenlal Kuttichira Source Type: research

A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement
Iran J Allergy Asthma Immunol. 2021 Aug 7;20(4):494-499.ABSTRACTNo effective antiviral drugs and vaccines are available for the treatment of patients with severe coronavirus 2019 (COVID-19). Therefore, available, safe, and inexpensive drugs and supplements such as melatonin are among the proposed options for controlling inflammation. We did a randomized, single-blind study in Imam Khomeini Hospital between June 30, 2020, and August 5, 2020. Mild to moderate COVID-19 patients aged 25-65 years were eligible to enter the study based on chest CT scan, clinical symptoms, and physician diagnosis. The intervention group was presc...
Source: Iranian Journal of Allergy, Asthma and Immunology - August 22, 2021 Category: Allergy & Immunology Authors: Zahra Alizadeh Nastaran Keyhanian Sara Ghaderkhani Simin Dashti-Khavidaki Raheleh Shokouhi Shoormasti Zahra Pourpak Source Type: research

Pages: 1  2  3  4  5  6